

CITATION REPORT

List of articles citing

Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer

DOI: 10.1007/s11523-021-00842-1
Targeted Oncology, 2021, 16, 847-856.

Source: <https://exaly.com/paper-pdf/91087277/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
5	Assay technologies facilitating drug discovery for ADP-ribosyl writers, readers and erasers. <i>BioEssays</i> , 2021 , 44, e2100240	4.1	2
4	Neuroprotective Effects of PARP Inhibitors in Models of Alzheimer's Disease.. <i>Cells</i> , 2022 , 11,	7.9	1
3	The Influence of PARP, ATR, CHK1 Inhibitors on Premature Mitotic Entry and Genomic Instability in High-Grade Serous BRCA-MUT and BRCAWT Ovarian Cancer Cells. <i>Cells</i> , 2022 , 11, 1889	7.9	0
2	Natural phytochemicals prevent side effects in BRCA-mutated ovarian cancer and PARP inhibitor treatment. 13,		0
1	A Screen Reveals Bexarotene, Sorafenib and Certain of its Analogues as Common and Effective Inhibitors of Growth of Bacteria that Grow on LB but not on McConkey Agar.		0